GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (STU:GE9) » Definitions » Book Value per Share

Genmab AS (STU:GE9) Book Value per Share : €77.34 (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Genmab AS Book Value per Share?

Genmab AS's book value per share for the quarter that ended in Mar. 2025 was €77.34.

During the past 12 months, Genmab AS's average Book Value Per Share Growth Rate was 16.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 19.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 20.70% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 32.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Genmab AS was 97.10% per year. The lowest was -40.50% per year. And the median was 18.85% per year.

Genmab AS's current price is €172.25. Its book value per share for the quarter that ended in Mar. 2025 was €77.34. Hence, today's PB Ratio of Genmab AS is 2.23.

During the past 13 years, the highest P/B Ratio of Genmab AS was 20.65. The lowest was 2.12. And the median was 8.43.

Good Sign:

Genmab AS stock PB Ratio (=2.2) is close to 10-year low of 2.12.


Genmab AS Book Value per Share Historical Data

The historical data trend for Genmab AS's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Book Value per Share Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.71 45.50 56.70 65.88 76.95

Genmab AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.39 65.08 67.83 76.95 77.34

Competitive Comparison of Genmab AS's Book Value per Share

For the Biotechnology subindustry, Genmab AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's PB Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's PB Ratio falls into.


;
;

Genmab AS Book Value per Share Calculation

Genmab AS's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(4,889-0)/64
=76.95

Genmab AS's Book Value Per Share for the quarter that ended in Mar. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(4,899-0)/63
=77.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Genmab AS  (STU:GE9) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Genmab AS Book Value per Share Related Terms

Thank you for viewing the detailed overview of Genmab AS's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines